{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Louisville&page=74&state=Kentucky", "query": { "state": "Kentucky", "city": "Louisville", "page": 74 }, "page_size": 10 }, "pagination": { "page": 74, "page_size": 10, "total_count": 5315, "total_pages": 532, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Louisville&page=75&state=Kentucky&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Louisville&page=73&state=Kentucky&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T08:21:05.532Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01975389", "title": "The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cardiovascular Disease" ], "interventions": [ { "name": "bococizumab (PF-04950615)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10564, "start_date": "2013-10-29", "completion_date": "2017-04-03", "has_results": true, "last_update_posted_date": "2019-05-01", "last_synced_at": "2026-11-15T08:21:05.532Z", "location_count": 518, "location_summary": "Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 328 more", "locations": [ { "city": "Athens", "state": "Alabama" }, { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01975389" }, { "nct_id": "NCT02009397", "title": "A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Louisville", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2012-02", "completion_date": "2016-11", "has_results": true, "last_update_posted_date": "2021-11-22", "last_synced_at": "2026-11-15T08:21:05.532Z", "location_count": 1, "location_summary": "Louisville, Kentucky", "locations": [ { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02009397" }, { "nct_id": "NCT05183035", "title": "Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Gemtuzumab Ozogamicin", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PedAL BCU, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "29 Days", "maximum_age": "21 Years", "sex": "ALL", "summary": "29 Days to 21 Years" }, "enrollment_count": 120, "start_date": "2022-10-01", "completion_date": "2031-04", "has_results": false, "last_update_posted_date": "2026-11-06", "last_synced_at": "2026-11-15T08:21:05.532Z", "location_count": 45, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05183035" }, { "nct_id": "NCT00229658", "title": "An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Type 1 Diabetes Mellitus", "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "pramlintide acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1297, "start_date": "2005-09", "completion_date": "2008-05", "has_results": true, "last_update_posted_date": "2015-03-25", "last_synced_at": "2026-11-15T08:21:05.532Z", "location_count": 107, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 104 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Encinitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00229658" }, { "nct_id": "NCT03959085", "title": "Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "B Acute Lymphoblastic Leukemia", "B Lymphoblastic Lymphoma", "Central Nervous System Leukemia", "Mixed Phenotype Acute Leukemia", "Testicular Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Calaspargase Pegol", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Inotuzumab Ozogamicin", "type": "BIOLOGICAL" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG", "OTHER", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "365 Days", "maximum_age": "25 Years", "sex": "ALL", "summary": "365 Days to 25 Years" }, "enrollment_count": 5951, "start_date": "2019-10-31", "completion_date": "2032-03-31", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-11-15T08:21:05.532Z", "location_count": 203, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03959085" }, { "nct_id": "NCT00000133", "title": "Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) - Outcome Study of Cryotherapy for Retinopathy of Prematurity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Retinopathy of Prematurity" ], "interventions": [ { "name": "Trans-scleral Cryotherapy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "National Eye Institute (NEI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "1 Year", "sex": "ALL", "summary": "Up to 1 Year" }, "enrollment_count": null, "start_date": "1986-01", "completion_date": "2003-08", "has_results": false, "last_update_posted_date": "2014-02-04", "last_synced_at": "2026-11-15T08:21:05.532Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000133" }, { "nct_id": "NCT03315143", "title": "Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Failure", "Type 2 Diabetes Mellitus", "Chronic Kidney Diseases" ], "interventions": [ { "name": "Sotagliflozin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lexicon Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10584, "start_date": "2017-12-19", "completion_date": "2020-07-08", "has_results": true, "last_update_posted_date": "2022-10-28", "last_synced_at": "2026-11-15T08:21:05.532Z", "location_count": 119, "location_summary": "Birmingham, Alabama • Sheffield, Alabama • Mesa, Arizona + 97 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sheffield", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03315143" }, { "nct_id": "NCT03654768", "title": "Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive" ], "interventions": [ { "name": "Bosutinib", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nilotinib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2018-10-24", "completion_date": "2028-07-01", "has_results": true, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-11-15T08:21:05.532Z", "location_count": 541, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 320 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03654768" }, { "nct_id": "NCT00733850", "title": "Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Kanglaite Injection plus gemcitabine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "KangLaiTe USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2008-08", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2015-06-19", "last_synced_at": "2026-11-15T08:21:05.532Z", "location_count": 42, "location_summary": "Muscle Shoals, Alabama • Casa Grande, Arizona • Burbank, California + 36 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Casa Grande", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Downey", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00733850" }, { "nct_id": "NCT00604643", "title": "Talent Aortic Cuff Stent Graft System Compassionate Use Registry", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Abdominal Aortic Aneurysms" ], "interventions": [ { "name": "TALENT Aortic Cuff Abdominal Stent Graft", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Medtronic Cardiovascular", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2021-11-02", "last_synced_at": "2026-11-15T08:21:05.532Z", "location_count": 50, "location_summary": "Montgomery, Alabama • Oakland, California • San Jose, California + 42 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Oakland", "state": "California" }, { "city": "San Jose", "state": "California" }, { "city": "Union City", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00604643" } ] }